Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ≥ 2
Fernandez, M., Wang, J., Ye, X., Kwong, WJ., Sherif, B., Hogue, S., & Sherrill, E. (2015). Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ≥ 2. SAGE Open, Advance Online Publication. Advance online publication. https://doi.org/10.1177/2050312115613350
Abstract
Among patients with atrial fibrillation and CHADS2 score ⩾ 2, the high-dose edoxaban regimen may offer similar efficacy to the other nonvitamin K antagonist oral anticoagulants but with a significant major bleeding benefit over rivaroxaban and dabigatran.
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.